Advanced search
1 file | 250.44 KB Add to list

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

(2019) LEUKEMIA. 33(10). p.2531-2535
Author
Organization
Keywords
CD37, SAFETY

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 250.44 KB

Citation

Please use this url to cite or link to this publication:

MLA
Stilgenbauer, Stephan, et al. “Phase 1 First-in-Human Trial of the Anti-CD37 Antibody BI 836826 in Relapsed/Refractory Chronic Lymphocytic Leukemia.” LEUKEMIA, vol. 33, no. 10, 2019, pp. 2531–35, doi:10.1038/s41375-019-0475-z.
APA
Stilgenbauer, S., Schleinitz, T. A., Eichhorst, B., Lang, F., Offner, F., Rossi, J.-F., … Zenz, T. (2019). Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. LEUKEMIA, 33(10), 2531–2535. https://doi.org/10.1038/s41375-019-0475-z
Chicago author-date
Stilgenbauer, Stephan, Therese Aurran Schleinitz, Barbara Eichhorst, Fabian Lang, Fritz Offner, Jean-Francois Rossi, Wilfried Schroyens, et al. 2019. “Phase 1 First-in-Human Trial of the Anti-CD37 Antibody BI 836826 in Relapsed/Refractory Chronic Lymphocytic Leukemia.” LEUKEMIA 33 (10): 2531–35. https://doi.org/10.1038/s41375-019-0475-z.
Chicago author-date (all authors)
Stilgenbauer, Stephan, Therese Aurran Schleinitz, Barbara Eichhorst, Fabian Lang, Fritz Offner, Jean-Francois Rossi, Wilfried Schroyens, Eric Van den Neste, Loic Ysebaert, Ute von Wangenheim, Uta Ursula Kress, Petra Blum, and Thorsten Zenz. 2019. “Phase 1 First-in-Human Trial of the Anti-CD37 Antibody BI 836826 in Relapsed/Refractory Chronic Lymphocytic Leukemia.” LEUKEMIA 33 (10): 2531–2535. doi:10.1038/s41375-019-0475-z.
Vancouver
1.
Stilgenbauer S, Schleinitz TA, Eichhorst B, Lang F, Offner F, Rossi J-F, et al. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. LEUKEMIA. 2019;33(10):2531–5.
IEEE
[1]
S. Stilgenbauer et al., “Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia,” LEUKEMIA, vol. 33, no. 10, pp. 2531–2535, 2019.
@article{8647161,
  author       = {{Stilgenbauer, Stephan and Schleinitz, Therese Aurran and Eichhorst, Barbara and Lang, Fabian and Offner, Fritz and Rossi, Jean-Francois and Schroyens, Wilfried and Van den Neste, Eric and Ysebaert, Loic and von Wangenheim, Ute and Kress, Uta Ursula and Blum, Petra and Zenz, Thorsten}},
  issn         = {{0887-6924}},
  journal      = {{LEUKEMIA}},
  keywords     = {{CD37,SAFETY}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{2531--2535}},
  title        = {{Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia}},
  url          = {{http://doi.org/10.1038/s41375-019-0475-z}},
  volume       = {{33}},
  year         = {{2019}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: